Peter H. O'Donnell to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Peter H. O'Donnell has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.499
-
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16.
Score: 0.380
-
Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer. 2007 Jan 15; 96(1):177; author reply 178-9.
Score: 0.066
-
Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73.
Score: 0.028
-
Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
Score: 0.025